ADC Therapeutics (ADCT) Non-Current Assets (2019 - 2026)

ADC Therapeutics has disclosed Non-Current Assets across 8 years of filings, most recently posting $14.7 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $14.7 million, up 1.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.0 million (down 52.48% YoY), and the FY2025 annual result was $16.8 million, down 45.27% from the prior year.
• Non-Current Assets came in at $14.7 million for Q1 2026 at ADC Therapeutics, down from $16.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $83.2 million in Q4 2022 to a low of $2.6 million in Q3 2025.
• The 5-year median for Non-Current Assets is $16.4 million (2024), against an average of $21.3 million.
• Across the five-year window, Non-Current Assets jumped 66.17% in 2024 and slumped 83.77% in 2025, its largest moves.
• ADC Therapeutics' Non-Current Assets stood at $83.2 million in 2022, then sank by 77.76% to $18.5 million in 2023, then surged by 66.17% to $30.7 million in 2024, then sank by 45.27% to $16.8 million in 2025, then decreased by 12.41% to $14.7 million in 2026.
• The last three Non-Current Assets figures came in at $14.7 million (Q1 2026), $16.8 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.